
Investor Relations
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.
Stock Market
NASDAQSNGX
Featured Presentation
QuickLinks
![]() |
Dr. Brian Poligone, Clinical Investigator for CTCL Phase 3 FLASH Study, Answers Questions About Patient Care and Treatment Options
IR Contacts
29 Emmons Drive
Suite B-10 Princeton, NJ 08540
Telephone: 609-538-8200
ir@soligenix.com
Subscribe For Alerts
If you would like to receive our Investor Relations updates, please sign up for email alerts.